{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT04676048",
            "orgStudyIdInfo": {
                "id": "ASC-HA-001"
            },
            "organization": {
                "fullName": "ASC Therapeutics",
                "class": "INDUSTRY"
            },
            "briefTitle": "ASC618 Gene Therapy in Hemophilia A Patients",
            "officialTitle": "Assessment of Safety and Preliminary Efficacy of ASC618 in Subjects With Severe and Moderately Severe Hemophilia A",
            "therapeuticArea": [
                "Other"
            ],
            "study": "gene-therapy-in-hemophilia-a-patients"
        },
        "statusModule": {
            "statusVerifiedDate": "2022-08",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2022-08-03",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2023-12",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2026-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2020-12-15",
            "studyFirstSubmitQcDate": "2020-12-17",
            "studyFirstPostDateStruct": {
                "date": "2020-12-19",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2023-01-30",
            "lastUpdatePostDateStruct": {
                "date": "2023-02-01",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "ASC Therapeutics",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "Currently, hemophilia A patients are managed with prophylactic or on-demand replacement therapy with recombinant FVIII or alternative therapeutics. The major challenges of current treatment regimens, such as the short half-life of hemophilia therapeutics with the need for frequent IV injections, encourage the current efforts for gene transfer therapy.\n\nThis study will evaluate the safety and preliminary efficacy of ASC618, an AAV vector encoding B-domain deleted codon-optimized human factor VIII under a synthetic liver-directed promoter"
        },
        "conditionsModule": {
            "conditions": [
                "Hemophilia A"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1",
                "PHASE2"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 12,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "ASC618",
                    "type": "EXPERIMENTAL",
                    "description": "Experimental Arm",
                    "interventionNames": [
                        "Biological: ASC618"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "ASC618",
                    "description": "ASC618 will be given as a single IV infusion",
                    "armGroupLabels": [
                        "ASC618"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of adverse events, and serious AEs",
                    "timeFrame": "12 months post-infusion"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Changes in FVIII activity levels from baseline",
                    "timeFrame": "12 months post-infusion"
                },
                {
                    "measure": "Annualized FVIII consumption",
                    "timeFrame": "12 months post-infusion"
                },
                {
                    "measure": "Annualized bleeding rate (ABR)",
                    "timeFrame": "12 months post-infusion"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* Male \u226518 years of age\n* Severe or moderately severe hemophilia A (FVIII activity \u2264 2 IU/dL) as evidenced by\n* medical history\n* Received FVIII prophylactic or on-demand replacement therapy for \u2265 150 accumulated\n* days (exposure days)\n* \u226512 bleeding episodes if receiving on-demand therapy over the preceding 12 months\n* BMI \u2264 30\n* Agree to use double-barrier contraceptive until at least 3 consecutive semen samples are negative after ASC-618 infusion\n\nExclusion Criteria:\n\n* Pre-existing immunity to AAV8 vector as defined by AAV8 total antibodies and neutralizing antibodies qualified tests.\n* Current inhibitors, or history of high titer FVIII inhibitors\n* Presence of \\> Grade 2 liver fibrosis on elastography/Fibroscan or comparable imaging methodology\n* History of chronic renal disease\n* Active infection or any immunosuppressive disorder\n* History of cardiac surgery and need anticoagulant therapy\n* Any cardiovascular / genetic risk factors for thromboembolic disorders\n* Evidence of active Hepatitis B, Hepatitis C, Human Immunodeficiency Virus (HIV)-1/2 or syphilis infection.\n* Receipt of any vector or gene transfer agent\n* Current antiviral therapy for hepatitis B or C",
            "healthyVolunteers": false,
            "sex": "MALE",
            "genderBased": true,
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Clinical Trial Manager, PhD",
                    "role": "CONTACT",
                    "phone": "(408) 495-3891",
                    "email": "gil.gonen@asctherapeutics.com"
                }
            ],
            "locations": [
                {
                    "facility": "Arkansas Children's Hospital",
                    "status": "RECRUITING",
                    "city": "Little Rock",
                    "state": "Arkansas",
                    "zip": "72202",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 34.74648,
                        "lon": -92.28959
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000006467",
                    "term": "Hemophilia A"
                }
            ],
            "ancestors": [
                {
                    "id": "D000025861",
                    "term": "Blood Coagulation Disorders, Inherited"
                },
                {
                    "id": "D000001778",
                    "term": "Blood Coagulation Disorders"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000020147",
                    "term": "Coagulation Protein Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                },
                {
                    "id": "D000030342",
                    "term": "Genetic Diseases, Inborn"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M9553",
                    "name": "Hemophilia A",
                    "asFound": "Hemophilia A",
                    "relevance": "HIGH"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23095",
                    "name": "Blood Coagulation Disorders, Inherited",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M21982",
                    "name": "Coagulation Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M23686",
                    "name": "Genetic Diseases, Inborn",
                    "relevance": "LOW"
                },
                {
                    "id": "T2710",
                    "name": "Hemophilia",
                    "asFound": "Hemophilia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T2711",
                    "name": "Hemophilia A",
                    "asFound": "Hemophilia A",
                    "relevance": "HIGH"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC16",
                    "name": "Diseases and Abnormalities at or Before Birth"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M8312",
                    "name": "Factor VIII",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "Coag",
                    "name": "Coagulants"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}